As AbbVie and Allergan wade through U.S. regulatory review of their pending $63 billion merger, the EU has given the pair hope their transaction will pass muster, according to a FiercePharma report. After offering a conditional approval for the deal in January pending the sale of one GI asset, the EU is now ready to offer its full blessing.
The European Commission has approved AbbVie and Allergan’s sale of late-stage candidate brazikumab, clearing the way for a final approval of the pair’s merger, AbbVie said in a release. The merger itself is pending a final close, but AbbVie said in a release the sale approval would “clear the pathway” to wrap up the transaction. The merger is also pending approval by the Irish High Court, AbbVie said.